SEC Form 3 · accession 0001144204-18-033545
Protalix BioTherapeutics, Inc. · PLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yaron Naos
Officer — Sr. VP, Operations
Period of report
May 29, 2018
Accepted (ET)
Jun 8, 2018 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001006281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 71,125 | D | ||
| Common StockF1 | holding | — | — | — | 128,438 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2 | $2.65 | holding | — | — | — | — | Feb 25, 2019 | Common Stock | 50,000 | — | D |
| Stock Options (Right to Buy)F3 | $6.90 | holding | — | — | — | — | Feb 25, 2020 | Common Stock | 115,000 | — | D |
| Stock Options (Right to Buy)F4 | $1.72 | holding | — | — | — | — | Mar 23, 2025 | Common Stock | 50,000 | — | D |
Explanation of responses
- F1To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Protalix BioTherapeutics, Inc. Amended and Restated 2006 Stock Incentive Plan (the "Plan") must be registered in the name of a trustee.
- F2The options are fully vested.
- F3The options are fully vested.
- F425% of the shares of common stock underlying the stock options vested on the first one-year anniversary of the date of grant and the remaining 75% of the shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing on such anniversary. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.